Cite
HARVARD Citation
Janzon, M. et al. (2003). Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart. 89 (3), pp. 287-292. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Janzon, M. et al. (2003). Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart. 89 (3), pp. 287-292. [Online].